Have you ever heard of Product Manager’s Disease? It’s when a Product Manager or Product Director attempts to execute as many tactics as possible without truly thinking through which tactics make the most sense for a given audience at a particular time. In other words, it’s throwing everything at the Read more…
Branding your peer-to-peer programs is more than just creating a logo or developing a marketing strategy—although marketing and branding are closely related, they are often confused. Marketing includes all of the commercial activities that are required to gain acceptance of your brand in the marketplace. Branding peer-to-peer programs is the Read more…
Regulated pharmaceutical prices are common in foreign countries, but the United States government has been reluctant to set pharmaceutical price ceilings. A recent online poll conducted by Pharmaceutical Executive asked its audience, which consists primarily of professionals working in the pharmaceutical industry, what their greatest concern is for the future of the Read more…
There is no excerpt because this is a protected post.
Rising healthcare costs in the United States have caused government, corporate, and association leaders to look for ways to make our healthcare system more efficient. Insurance provider and Affordable Care Act plans both provide for preventative care in order to keep long term costs down for the patient and the Read more…
In pharma marketing, messaging and targeting are everything. The most appropriate words delivered to a carefully selected group of healthcare professionals leads to patients getting the best treatments. Or does it? When listening to patients and physicians separately, we often get different answers. Asking a patient how a diagnosis was delivered Read more…
The last decade has brought a variety of innovative cancer treatment options to the market. A 2009 study conducted by PhRMA compiled a list of 129 medications in development to treat Leukemia, 122 to treat lung cancer, and 106 to treat breast cancer[1]. The number of oncology patients has steadily grown Read more…
Association season is here. It’s that time of year to pack your bags and get away for a few days to meet up with old friends, see the competition’s abstracts, learn about the ground-breaking science, see the proof behind your product’s science, and hear about the late-breaking clinical trials. There is Read more…
At the heart of your advisory board, you should find engaging, and even impassioned, discussions by Key Opinion Leaders (KOLs). They want to help you make a difference. Planning for effective communication within your advisory board will allow for a higher impact advisory board so you can glean more insights Read more…
What a move by GlaxoSmithKline, they are no longer paying speakers for speaker programs beginning in 2016. I have attended many speaker programs throughout my career. They’re usually a gathering of local clinicians, led by a Key Opinion Leader (KOL) who can help elucidate some important information, and are facilitated Read more…